-
Je něco špatně v tomto záznamu ?
"Non-Taxifolin" Derived Flavonolignans: Phytochemistry and Biology
CS. Chambers, K. Valentova, V. Kren,
Jazyk angličtina Země Nizozemsko
Typ dokumentu časopisecké články, práce podpořená grantem, přehledy
Odkazy
PubMed
26429716
DOI
10.2174/1381612821666151002112720
Knihovny.cz E-zdroje
- MeSH
- antiflogistika chemie izolace a purifikace farmakologie MeSH
- antioxidancia chemie izolace a purifikace farmakologie MeSH
- antitumorózní látky chemie izolace a purifikace farmakologie MeSH
- flavonolignany chemie izolace a purifikace farmakologie MeSH
- fytonutrienty chemie izolace a purifikace farmakologie MeSH
- lidé MeSH
- ostropestřec mariánský MeSH
- quercetin analogy a deriváty chemie izolace a purifikace farmakologie MeSH
- rostlinné extrakty chemie izolace a purifikace farmakologie MeSH
- Staphylococcus aureus účinky léků MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- přehledy MeSH
Flavonolignans are plant natural products, composed of a flavonoid moiety and a lignan (phenylpropanoid) part. Current literature focuses on flavonolignans formed from taxifolin and coniferyl alcohol as e.g. silybin and its congeners from fruit extract from the purple variety of the milk thistle (Silybum marianum) denoted as "silymarin". This review describes chemistry and biological activity of so far neglected "non-taxifolin" based flavonolignans, derived from apigenin, luteolin, tricin, chrysoeriol, naringenin and eriodictyol, as the flavonoid part. Up-to-date knowledge on hydnocarpin, hydnocarpin-D, pseudotsuganol, hydnowightin, neohydnocarpin, palstatin, salcolins A and B, anastatins A and B, sinaiticin, silyamandin and silandrin is summarized in the present paper. Most of non-taxifolin derived flavonolignans have been shown to exhibit in vitro and/or in vivo anti-hepatotoxic, anti-oxidant, free radical scavenging, anti-inflammatory, anti-proliferative, anti-cancer, chemotherapy potentiating, anti-melanogenic, anti-bacterial, vasorelaxing, anti-platelet aggregation and/or hypotriglyceridemic activity, often stronger than silybin. Many of these compounds inhibited Staphylococcus aureus multidrug resistance pump NorA and sensitized multidrug resistant cancer cell lines showing a potential as adjuvants. Non-taxifolin derived flavonolignans are a relatively unexplored group of compounds with interesting biological activity and great application potential. Their detailed study could provide a new insight into the biomimetic synthesis in order to obtain new compounds with greater activity and identify new lead structures for the biomedicinal research.
- 000
- 00000naa a2200000 a 4500
- 001
- bmc16028152
- 003
- CZ-PrNML
- 005
- 20161021111858.0
- 007
- ta
- 008
- 161005s2015 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.2174/1381612821666151002112720 $2 doi
- 035 __
- $a (PubMed)26429716
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Chambers, Christopher S $u Laboratory of Biotransformation, Institute of Microbiology, Czech Academy of Sciences, Vídenská 1083, CZ 142 20 Prague, Czech Republic. christopher.chambers@biomed.cas.cz.
- 245 10
- $a "Non-Taxifolin" Derived Flavonolignans: Phytochemistry and Biology / $c CS. Chambers, K. Valentova, V. Kren,
- 520 9_
- $a Flavonolignans are plant natural products, composed of a flavonoid moiety and a lignan (phenylpropanoid) part. Current literature focuses on flavonolignans formed from taxifolin and coniferyl alcohol as e.g. silybin and its congeners from fruit extract from the purple variety of the milk thistle (Silybum marianum) denoted as "silymarin". This review describes chemistry and biological activity of so far neglected "non-taxifolin" based flavonolignans, derived from apigenin, luteolin, tricin, chrysoeriol, naringenin and eriodictyol, as the flavonoid part. Up-to-date knowledge on hydnocarpin, hydnocarpin-D, pseudotsuganol, hydnowightin, neohydnocarpin, palstatin, salcolins A and B, anastatins A and B, sinaiticin, silyamandin and silandrin is summarized in the present paper. Most of non-taxifolin derived flavonolignans have been shown to exhibit in vitro and/or in vivo anti-hepatotoxic, anti-oxidant, free radical scavenging, anti-inflammatory, anti-proliferative, anti-cancer, chemotherapy potentiating, anti-melanogenic, anti-bacterial, vasorelaxing, anti-platelet aggregation and/or hypotriglyceridemic activity, often stronger than silybin. Many of these compounds inhibited Staphylococcus aureus multidrug resistance pump NorA and sensitized multidrug resistant cancer cell lines showing a potential as adjuvants. Non-taxifolin derived flavonolignans are a relatively unexplored group of compounds with interesting biological activity and great application potential. Their detailed study could provide a new insight into the biomimetic synthesis in order to obtain new compounds with greater activity and identify new lead structures for the biomedicinal research.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a antiflogistika $x chemie $x izolace a purifikace $x farmakologie $7 D000893
- 650 _2
- $a antitumorózní látky $x chemie $x izolace a purifikace $x farmakologie $7 D000970
- 650 _2
- $a antioxidancia $x chemie $x izolace a purifikace $x farmakologie $7 D000975
- 650 _2
- $a flavonolignany $x chemie $x izolace a purifikace $x farmakologie $7 D044947
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a ostropestřec mariánský $7 D020944
- 650 _2
- $a fytonutrienty $x chemie $x izolace a purifikace $x farmakologie $7 D064209
- 650 _2
- $a rostlinné extrakty $x chemie $x izolace a purifikace $x farmakologie $7 D010936
- 650 _2
- $a quercetin $x analogy a deriváty $x chemie $x izolace a purifikace $x farmakologie $7 D011794
- 650 _2
- $a Staphylococcus aureus $x účinky léků $7 D013211
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Valentova, Katerina
- 700 1_
- $a Kren, Vladimir
- 773 0_
- $w MED00007893 $t Current pharmaceutical design $x 1873-4286 $g Roč. 21, č. 38 (2015), s. 5489-500
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/26429716 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20161005 $b ABA008
- 991 __
- $a 20161021112307 $b ABA008
- 999 __
- $a ok $b bmc $g 1166466 $s 952782
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2015 $b 21 $c 38 $d 5489-500 $i 1873-4286 $m Current pharmaceutical design $n Curr Pharm Des $x MED00007893
- LZP __
- $a Pubmed-20161005